Drugs / Caldonirimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05606263 | Nov 2022 → Nov 2023 | cervical cancer | Xi'an Jiaotong University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Caldonirimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05606263 ↗ |
| Modality | Monoclonal antibody | “Caldonirimab, a PD-1/CTLA-4 bispecific antibody” NCT05606263 ↗ |